`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`v.
`ALMIRALL, LLC
`Patent Owner
`
`Case: IPR2019-01095
`U.S. Patent No. 9,517,219
`
`PETITIONER’S EXHIBIT LIST
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`US_139681447v1_391026-00295
`
`
`
`Mylan
`Exhibit #
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`1006
`1007
`1008
`
`1009
`
`1010
`1011
`1012
`1013
`
`1014
`
`1015
`
`1016
`1017
`1018
`
`Description
`
`U.S. Patent No. 9,517,219
`Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS,
`M.R.Pharm.S.
`Curriculum Vitae for Bozena B. Michniak-Kohn, Ph.D., FAAPS,
`M.R.Pharm.S.
`International Patent Application Publication No. WO
`2009/061298 (“Garrett”)
`International Application Publication No. WO 2010/072958
`(“Nadau-Fourcade”)
`Certification for Translation of WO 2010/072958
`U.S. Patent Publication No. 2006/0204526 (“Lathrop”)
`U.S. Patent Publication No. 2010/0029781 (“Morris”)
`Osborne, D.W., “Diethylene glycol monoethyl ether: an
`emerging solvent in topical dermatology products,” J. Cosmetic
`Derm. 10:324-329 (2011) (“Osborne I”)
`Physician’s Desk Reference, 65th
`ed., pp. 599-602 (2011)
`(ACZONE Gel 5% Label)
`U.S. Patent No. 7,820,186 (“Orsoni”)
`Epiduo Product Label, approved December 8, 2008
`(“Epiduo Label”)
`U.S. Patent Publication No. 2007/0190019 (“Guo”)
`Rowe, R.C. et al. (Eds.), Handbook of Pharmaceutical
`Excipients, 6th Ed., Pharmaceutical Press: London, UK (2009)
`Bonacucina, G., et al., “Characterization and Stability of
`Emulsion Gels Based on Acrylamide/Sodium Acryloyldimethyl
`Taurate Copolymer,” AAPS PharmaSciTech 10:368-375 (2009)
`(“Bonacucina”)
`U.S. Patent No. 5,863,560 (“Osborne II”)
`File History of U.S. Patent No. 9,517,219
`Declaration of Elaine S. Gilmore, M.D., Ph.D.
`
`US_139681447v1_391026-00295
`
`
`
`Mylan
`Exhibit #
`1019
`1020
`1021
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`Description
`
`Curriculum Vitae for Elaine S. Gilmore, M.D., Ph.D.
`Affidavit of Christopher Butler
`Intentionally left blank
`Wozel, D., “Innovative Use of Dapsone” Dermatol. Clin. 28: 599–
`610 (2010) (“Wozel”)
`Thiboutot, D., et al., “Pharmacokinetics of Dapsone Gel, 5% for
`the Treatment of Acne Vulgaris” Clin. Pharmacokinet. 46: 697-
`712 (2007) (“Thiboutot”)
`Nguyen, R. and Su, J., “Treatment of Acne Vulgaris” Pediatrics and
`Child Health 21: 119-125 (2010) (“Nguyen”)
`Williams, H., et al., “Acne vulgaris” Lancet 379: 361–72
`(2012) (“Williams”)
`SepineoTM P 600 Brochure
`Barclay, L., “Use of Topical Corticosteroids for Dermatologic
`Conditions Reviewed” Medscape - Jan 21, 2009, accessed from
`https://www.medscape.com/viewarticle/587159_print (“Barclay”)
`Remington: The Science and Practice of Pharmacy, 21st
`Ed., Lippincott Williams & Wilkins: Baltimore, MD (2005)
`(“Remington”)
`Kim, J-Y., et al., “Rheological properties and microstructures of
`Carbopol gel network system,” Colloid. Polym. Sci. 281:614–
`623(2003) (“Kim”)
`Intentionally left blank
`Spain's Almirall bets on dermatology with $650 million U.S. deal,
`Retrieved from https://www.reuters.com/article/us-allergan-m-a-
`almirall/spains-almirall-bets-on-dermatology-with-650-million-us-
`deal-idUSKBN1KO10N, last accessed October 26, 2018
`Piskin, S. et al. “A review of the use of adapalene for the treatment
`of acne vulgaris,” Therapeutics and Clinical Risk Management
`3(4): 621–624 (2007) (“Piskin”)
`Intentionally left blank
`
`US_139681447v1_391026-00295
`
`
`
`Mylan
`Exhibit #
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`Description
`
`Andersson, D., “Evonik-Degussa expands its
`cooperation with Alsiano,” Pharma & Healthcare News : 1-10
`(2007)
`Declaration of Audra L. Stinchcomb, Ph.D.
`
`Curriculum Vitae for Audra L. Stinchcomb, Ph.D.
`
`Declaration of Marc Serota, M.D.
`
`Curriculum Vitae for Marc Serota, M.D.
`
`US_139681447v1_391026-00295
`
`